STOCK TITAN
  1. Home
  2. Sec-filings
  3. GLUE
  4. [Form 4] Monte Rosa Therapeutics, Inc. Insider Trading Activity

Monte Rosa (NASDAQ: GLUE) COO exercises options and sells 2,176 shares under plan

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Monte Rosa Therapeutics Chief Operating Officer Jennifer Champoux reported an exercise-and-sell transaction in company stock. On May 22, 2026, she exercised stock options to acquire 2,176 shares of common stock at $3.98 per share and, on the same date, completed an open-market sale of 2,176 shares at $19.00 per share. After these transactions, she directly held 62,371 shares of Monte Rosa Therapeutics common stock. The filing notes that the transactions were made under a pre-arranged Rule 10b5-1 trading plan adopted on February 19, 2026, indicating they were scheduled in advance.

Positive

  • None.

Negative

  • None.
Insider Champoux Jennifer
Role Chief Operating Officer
Sold 2,176 shs ($41K)
Type Security Shares Price Value
Exercise Stock Option (Right to Buy) 2,176 $0.00 --
Exercise Common Stock 2,176 $3.98 $9K
Sale Common Stock 2,176 $19.00 $41K
Holdings After Transaction: Stock Option (Right to Buy) — 37,824 shares (Direct, null); Common Stock — 64,547 shares (Direct, null)
Footnotes (1)
  1. These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 19, 2026. 25% of this option vested on May 28, 2025, with the remainder vesting in 36 substantially equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.
Shares sold 2,176 shares Open-market sale of common stock on May 22, 2026
Sale price $19.00 per share Price for 2,176 common shares sold
Shares acquired via exercise 2,176 shares Common stock from option exercise on May 22, 2026
Option exercise price $3.98 per share Stock option (right to buy) conversion price
Shares owned after 62,371 shares Direct common stock holdings following transactions
Rule 10b5-1 adoption date February 19, 2026 Trading plan governing May 22, 2026 transactions
Option expiration June 3, 2034 Expiration date of the exercised stock option
Rule 10b5-1 trading plan regulatory
"These transactions were effected pursuant to a Rule 10b5-1 trading plan"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
Stock Option (Right to Buy) financial
"security_title": "Stock Option (Right to Buy)""
open-market sale financial
"transaction_action": "open-market sale""
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
Chief Operating Officer other
"officer_title": "Chief Operating Officer""
A chief operating officer (COO) is a senior executive responsible for overseeing the day-to-day activities of a company, ensuring that all parts of the organization work smoothly and efficiently. They often act like a company's operational quarterback, translating strategic plans into practical actions. For investors, the COO's effectiveness can influence a company's performance and stability, making them an important figure in assessing the company's management strength.
derivative exercise/conversion financial
"transaction_action": "derivative exercise/conversion""
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Champoux Jennifer
(Last)(First)(Middle)
MONTE ROSA THERAPEUTICS, INC.
321 HARRISON AVENUE, SUITE 900
(Street)
BOSTON MASSACHUSETTS 02118
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
Monte Rosa Therapeutics, Inc. [ GLUE ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
Chief Operating Officer
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
05/22/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock05/22/2026M(1)2,176A$3.9864,547D
Common Stock05/22/2026S(1)2,176D$1962,371D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy)$3.9805/22/2026M(1)2,176 (2)06/03/2034Common Stock2,176$037,824D
Explanation of Responses:
1. These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 19, 2026.
2. 25% of this option vested on May 28, 2025, with the remainder vesting in 36 substantially equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.
/s/ Phil Nickson, Attorney-in-Fact05/26/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did GLUE executive Jennifer Champoux report?

Jennifer Champoux reported an exercise-and-sell transaction. She exercised stock options for 2,176 Monte Rosa Therapeutics common shares at $3.98 and sold 2,176 shares in an open-market trade at $19.00, all dated May 22, 2026.

How many Monte Rosa Therapeutics (GLUE) shares does Jennifer Champoux hold after this Form 4?

After the reported transactions, Champoux holds 62,371 shares. The Form 4 shows her direct ownership of Monte Rosa Therapeutics common stock following the May 22, 2026 option exercise and matching open-market sale of 2,176 shares.

At what prices did the GLUE insider exercise options and sell shares?

The option exercise price was $3.98 and the sale price was $19.00. Champoux exercised stock options for 2,176 shares at $3.98 per share and sold 2,176 common shares in the open market at $19.00 per share.

Were Jennifer Champoux’s GLUE stock transactions under a Rule 10b5-1 plan?

Yes, the transactions were made under a Rule 10b5-1 trading plan. The filing states the plan was adopted on February 19, 2026, meaning the May 22, 2026 exercise and sale were pre-scheduled rather than discretionary.

What type of derivative security did the GLUE insider exercise?

Champoux exercised a stock option (right to buy) security. The option covered 2,176 underlying Monte Rosa Therapeutics common shares at a $3.98 exercise price and had an expiration date of June 3, 2034, according to the Form 4.

What role does Jennifer Champoux hold at Monte Rosa Therapeutics (GLUE)?

Jennifer Champoux serves as Chief Operating Officer. The Form 4 identifies her as an officer of Monte Rosa Therapeutics with the title Chief Operating Officer, providing context for her insider status in reporting equity transactions.